On Air Now

Current Show

The Sean Hannity Show   2:00 PM - 5:00 PM

Call the Sean Hannity Show at 800-941-7326

Show Info »

Upcoming Shows

Program Schedule »


Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI


Current Conditions(Wausau,WI 54403)

More Weather »
75° Feels Like: 75°
Wind: WSW 10 mph Past 24 hrs - Precip: 0”
Current Radar for Zip


Mostly Sunny 74°


Clear 53°


Mostly Sunny 79°


Breaking News

URGENT: Video shows beheading of second American journalist

DUBAI (Reuters) - The Islamic State militant group released a video purporting to show the beheading of U.S. hostage Steven Sotloff, the SITE monitoring service reported on Tuesday. A masked figure in the video also issued a threat against a British hostage, a man the group named as David Haines, and warned governments to back off "this evil alliance of America against the Islamic State", the monitoring service said. (Reporting by William Maclean, Editing by Angus MacSwan)

Read More »

FDA approves once-monthly Abilify for schizophrenia

(Reuters) - Regulators on Thursday approved a once-monthly injectable form of Abilify, the blockbuster treatment for schizophrenia, which will be sold by Japanese drugmaker Otsuka and Danish drug group Lundbeck.

In July 2012, the Food and Drug Administration declined to approve the medicine, Abilify Maintena, citing deficiencies from an inspection of a third-party supplier of sterile water. Otsuka and Lundbeck resubmitted their marketing application soon afterward, after working with an alternative supplier.

About 1 percent of adults in the United States are believed to have schizophrenia, a disorder of thought processes that can involve hallucinations, delusions and poor emotional responsiveness.

The new formulation of Abilify is meant to provide long-term prevention of relapses from schizophrenia symptoms, particularly for patients who don't faithfully take their anti-psychosis medicines.

But the medicine has a convenience disadvantage. It comes in a "cake" form, which must be diluted with sterile water for injection. That means it has to be given by a healthcare professional.

For a decade, Otsuka and Bristol-Myers Squibb had co-marketed the once-daily basic formulation of Abilify, which had global sales of $2.8 billion in 2012. Under an updated partnership agreement, Otsuka early this year began to take on complete marketing responsibility for basic Abilify, but Bristol-Myers will continue to manufacture the medicine and share in revenue from it.

(Reporting By Ransdell Pierson and Ashley Lau in New York; Editing by Jan Paschal)

(This story was refiled to correct the stock symbol for Otsuka in the first paragraph to for Otsuka Holdings Co Ltd from for Otsuka)